Literature DB >> 22287434

Lateral frontal sinus access in endoscopic skull-base surgery.

Daniel G Timperley1, Catherine Banks, Daniel Robinson, Jason Roth, Raymond Sacks, Richard J Harvey.   

Abstract

BACKGROUND: The modified endoscopic Lothrop (MELP) or Draf III procedure can provide extended endoscopic access to the frontal sinus. The ability to access the entire frontal sinus entirely endoscopically is often debated and there is little published data to predict access based on tumor location.
METHODS: MELP was performed in 10 cadaver heads. Access was defined as the ability to contact the bone under vision with the head of a 70-degree diamond burr. Access was assessed in 3 areas: the orbital roof and the anterior and posterior walls of the frontal sinus. Endpoints were defined in millimeters from medial orbit and lateral quartile zones.
RESULTS: Complete lateral access was excellent anterior and posterior in 95% of sinuses (mean 15.5 ± 7.8 mm and 15.4 ± 7.7 mm, respectively). Access to the orbital roof was limited (10.3 ± 4.6 mm; p = 0.01 comparing anterior and posterior). For sinuses pneumatized beyond the midorbital point, only 10% of lateral orbital roofs were contacted. Orbital roof access correlated with the anteroposterior (AP) distance between the olfactory fossa and outer periosteum of the frontal beak (r = 0.6, p < 0.01).
CONCLUSION: Lateral endoscopic access to the walls of the frontal sinus is excellent except for the sinus floor. Access to the orbital roof is reliable in the medial quarter only and minimal lateral to the midorbital point. The ability to predict the areas accessible by the endoscopic approach and those areas that might require ancillary approaches is important for both surgical planning and patient expectations.
Copyright © 2011 American Rhinologic Society-American Academy of Otolaryngic Allergy, LLC.

Entities:  

Mesh:

Year:  2011        PMID: 22287434     DOI: 10.1002/alr.20042

Source DB:  PubMed          Journal:  Int Forum Allergy Rhinol        ISSN: 2042-6976            Impact factor:   3.858


  7 in total

Review 1.  Comprehensive review on endonasal endoscopic sinus surgery.

Authors:  Rainer K Weber; Werner Hosemann
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2015-12-22

2.  Transorbital neuroendoscopic management of sinogenic complications involving the frontal sinus, orbit, and anterior cranial fossa.

Authors:  Jae H Lim; Maya G Sardesai; Manuel Ferreira; Kris S Moe
Journal:  J Neurol Surg B Skull Base       Date:  2012-11-15

3.  Impact of prone, supine and oblique patient positioning on CBCT image quality, contrast-to-noise ratio and figure of merit value in the maxillofacial region.

Authors:  Juha Koivisto; Maureen van Eijnatten; Jorma Järnstedt; Kirsi Holli-Helenius; Prasun Dastidar; Jan Wolff
Journal:  Dentomaxillofac Radiol       Date:  2017-04-07       Impact factor: 2.419

4.  Gigantic paranasal sinuses osteomas: clinical features, management considerations, and long-term outcomes.

Authors:  Evangelos Giotakis; Valentinos Sofokleous; Alexander Delides; Andriana Razou; Georgios Pallis; Alexandra Karakasi; Pavlos Maragoudakis
Journal:  Eur Arch Otorhinolaryngol       Date:  2020-10-16       Impact factor: 2.503

Review 5.  Minimally invasive surgery of the anterior skull base: transorbital approaches.

Authors:  Holger G Gassner; Franziska Schwan; Karl-Michael Schebesch
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2016-07-11

6.  Origin site-based staging system of sinonasal inverted papilloma for application to endoscopic sinus surgery.

Authors:  Yifan Meng; Gaoli Fang; Xiangdong Wang; Xiaohong Song; Kuiji Wang; Hongfei Lou; Wenyu She; Long Qin; Mei Lv; Tao Zhang; Tiejun Yuan; Yanli Tao; Xun Meng; Luo Zhang; Chengshuo Wang
Journal:  Head Neck       Date:  2018-12-15       Impact factor: 3.147

7.  Endoscopic marsupialisation of the lateral frontal sinus mucocele with orbital extension: a case report.

Authors:  Hadi Sharouny; Prepageran Narayanan
Journal:  Iran Red Crescent Med J       Date:  2014-12-15       Impact factor: 0.611

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.